跳至主要内容
临床试验/NCT04162314
NCT04162314Unknown2 期

The Role of β-1,3/1,6-D-Glucan From Extract of Indonesian Ganoderma Lucidum Mycelium as a Combination Therapy With Methylprednisolone for Treatment of Non-infectious and Idiopathic Uveitis: A Double-blind Randomized Pilot Study

Fakultas Kedokteran Universitas Indonesia1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2020年1月21日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
20
试验地点
1
主要终点
Change in anterior chamber inflammatory cells grading

研究概览

简要总结

To investigate the effect of Beta-1,3/1,6-D-Glucan from mycelium extract of Indonesian Ganoderma lucidum as an adjuvant to methylprednisolone for non-infectious and idiopathic uveitis

详细描述

Patients with non-infectious and idiopathic uveitis will receive standard treatment with methylprednisolone, but will be randomized to receive either Beta-1,3/1,6-D-Glucan from mycelium extract of Indonesian Ganoderma lucidum or placebo. Follow up will be performed on week-2, week-4, week-6, month-2, and month-3. Outcomes measured are anterior chamber cells, visual acuity, and serum TNF-alpha levels.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with non-infectious and idiopathic uveitis.
  • Indicated to receive oral steroid and have signs of anterior segment inflammation.
  • Anterior chamber inflammation >= +2 according to SUN criteria.
  • Age between 18 and 65 years old, good general condition, consented to be involved in the research, and are willing to come regularly according to follow up schedule.

排除标准

  • Received systemic steroid and/other immunosuppressive drugs two weeks before the start of the trial.
  • Received antibiotics one week before the start of the trial.
  • Contraindicated to oral steroid.
  • Other primary ocular disorder, such as glaucoma, anterior segment dysgenesis, or others.
  • Pregnant and nursing women.
  • Patients with history of hypersensitivity/ allergy to Ganoderma species or other fungi.

研究组 & 干预措施

Control

Placebo Comparator

This group received combination of placebo capsules with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days

干预措施: Placebos (Drug)

Experimental

Experimental

This group received combination of mycelium extract of Ganoderma lucidum capsule containing 180 mg Beta-1,3/1,6-D-Glucan with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days

干预措施: Beta-1,3/1,6-D-Glucan Ganoderma lucidum (Drug)

结局指标

主要结局

Change in anterior chamber inflammatory cells grading

时间窗: Baseline, week-2, week-4, week-6, month-2, month-3

Change in anterior chamber inflammatory cells grading according to SUN nomenclature (0, 0.5+, 1+, 2+, 3+, 4+). 0 is minimum value (better outcome) and +4 is maximum value (worse outcome).

Change of serum TNF-alpha level

时间窗: Baseline, week-6, month-3

Change of serum TNF-alpha level

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hasianalumban

Ophthalmology resident

Fakultas Kedokteran Universitas Indonesia

研究点 (1)

Loading locations...

相似试验